Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke

In acute ischemic stroke, the only FDA-approved drug; recombinant tissue plasminogen activator (rt-PA) is limited by restricted time-window due to an enhanced risk of hemorrhagic transformation which is thought to be caused by metalloproteinase (MMP). In experimental stroke inhibitors of the mitogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Orset, Cyrille, Arkelius, Kajsa, Anfray, Antoine, Warfvinge, Karin, Vivien, Denis, Ansar, Saema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184783/
https://www.ncbi.nlm.nih.gov/pubmed/34099834
http://dx.doi.org/10.1038/s41598-021-91469-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184783/
https://www.ncbi.nlm.nih.gov/pubmed/34099834
http://dx.doi.org/10.1038/s41598-021-91469-9

Ejemplares similares